U.S. markets open in 3 hours 29 minutes

Enzolytics Inc. (ENZC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1035-0.0160 (-13.39%)
At close: 3:59PM EDT

Enzolytics Inc.

2000 North Central Expressway
Plano, TX 75074
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Charles S. CotropiaCEO, Pres & DirectorN/AN/AN/A
Mr. Rodney BarringtonChief Operating OfficerN/AN/AN/A
Mr. Harry H. Zhabilov Jr.CSO & DirectorN/AN/A1967
Dr. Joseph P. Cotropia M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.

Corporate Governance

Enzolytics Inc. ’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.